In a significant step toward combating India's growing obesity epidemic, Danish pharmaceutical major Novo Nordisk has launched its globally acclaimed anti-obesity drug Wegovy in India. The drug, which contains semaglutide as its active ingredient, is indicated for chronic weight management and the reduction of major cardiovascular risks in overweight and obese adults. Offered in five dose strengths through a once-weekly injectable pen device, Wegovy is priced between Rs. 17,345 and Rs. 26,050 per month. With 254 million Indians living with obesity, Novo Nordisk is targeting broad nationwide access and collaboration with healthcare stakeholders to position Wegovy as a transformational treatment option.
Semaglutide Enters India with Broader Clinical Scope
Novo Nordisk, already a dominant player in India’s insulin therapy segment, has expanded its footprint by launching Wegovy, a semaglutide-based medication aimed at addressing obesity and associated cardiovascular conditions. Unlike its diabetes-focused counterpart Ozempic—which contains the same active molecule but is yet to be launched in India—Wegovy is formulated specifically for weight loss and cardiometabolic risk reduction.
The drug will be made available across urban and rural regions in five escalating dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg, all administered through Novo Nordisk’s proprietary once-weekly injectable pen device.
India’s Obesity Burden: A Public Health Emergency
The decision to launch Wegovy in India is underscored by stark public health data. According to the INDIAB study, India currently has 254 million individuals with generalised obesity and 351 million with abdominal obesity, ranking third globally in terms of overall overweight and obese populations.
Speaking on the launch, Vikrant Shrotriya, Managing Director of Novo Nordisk India, emphasized that obesity in India is not merely a lifestyle issue but a chronic disease with significant economic consequences. “Obesity is projected to cost India 1.59% of its GDP by 2030, rising to 2.5% by 2050–2060 if unchecked,” he warned.
Mechanism of Action: Targeting the Brain’s Appetite Centers
Wegovy acts on brain regions responsible for appetite regulation, reducing hunger, enhancing satiety, and curbing food cravings. Clinical studies have demonstrated that semaglutide helps improve insulin sensitivity, reduces cardiometabolic risk factors, and can lead to substantial weight loss when used alongside diet and exercise.
Novo Nordisk is not targeting a specific sales figure in India; instead, it is focusing on awareness, accessibility, and affordability, aiming to educate healthcare professionals and patients on obesity as a treatable chronic condition.
Commercial Strategy: Localized Pricing and Strategic Collaborations
Wegovy’s India-specific pricing strategy ensures that the initial dose levels are uniformly priced, making early treatment stages more accessible. Monthly treatment costs range between Rs. 17,345 and Rs. 26,050, depending on the dose. The product is being imported from Denmark, with sufficient supply chains currently in place to meet anticipated demand.
Novo Nordisk also signaled its openness to partnerships with hospitals, clinics, doctors, and even state governments to scale distribution and raise public awareness.
Shrotriya called this launch one of the company’s most ambitious rollouts in India, adding, “We are not playing a volume game. We are playing a power game. And the power lies in delivering innovation that addresses unmet medical needs.”
Patent Expiry and the Prospect of Competition
The semaglutide molecule is expected to go off-patent next year, and Novo Nordisk is already preparing for competitive entry in the segment. “We welcome competition,” said Shrotriya, “because we believe India needs more players to address the enormity of the problem.”
He added that the company’s longstanding credibility in protein and peptide chemistry, along with its delivery technologies, will continue to give it an edge even after generics enter the market.
Global Context and Domestic Implications
Globally, the semaglutide franchise is approaching USD 20 billion in annual sales, with Wegovy and Ozempic driving substantial demand in both obesity and diabetes segments. India’s entry into this therapeutic landscape is expected to broaden treatment access and improve quality of life for millions.
Wegovy’s arrival follows closely behind the March 2025 launch of Eli Lilly’s Mounjaro, further intensifying competition in the high-growth weight-loss therapeutics market.
Conclusion: A Timely Intervention for a National Crisis
Novo Nordisk’s launch of Wegovy in India signals a turning point in the country’s fight against obesity. With an extensive distribution strategy, physician engagement plans, and policy-level collaboration opportunities, the company is poised to reshape how obesity is perceived and treated across the healthcare spectrum.
As the country grapples with the dual challenge of metabolic diseases and cardiovascular risk, Wegovy offers a scientifically backed, patient-centric solution—delivered through an established global leader in therapeutic innovation.
Comments